Position in EOLS
as of Mar 31, 2026
· filed May 29, 2026
Position Value
$5,289,002
-$17,504,302 QoQ
Shares Held
1,286,862
-48.0% QoQ
Ownership
1.95%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2023
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in EOLS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026PERCEPTIVE ADVISORS LLC holds $200,430,720 across 5 Drug Manufacturers - Specialty & Generic names. EOLS ranks #4 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
8,284,882 | $115,159,859 | |
| 2 | BCRX |
Biocryst Pharmaceuticals Inc
|
7,434,033 | $70,771,994 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
65,050 | $8,569,687 | |
| 4 | EOLS |
Evolus, Inc.
This page
|
1,286,862 | $5,289,002 | |
| 5 | CPIX |
Cumberland Pharmaceuticals Inc
|
196,978 | $640,178 |
All Filings in EOLS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,289,002 | 1,286,862 | Shares | Sole | 2026-05-29 | |
| 2025-06-30 | $22,793,304 | 2,474,843 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $49,673,578 | 4,129,142 | Shares | Sole | 2025-08-06 | |
| 2024-12-31 | $56,810,139 | 5,145,846 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $86,777,276 | 5,356,622 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $62,428,708 | 5,753,798 | Shares | Sole | 2024-08-16 | |
| 2024-03-31 | $80,553,172 | 5,753,798 | Shares | Sole | 2024-08-06 | |
| 2023-12-31 | $41,734,854 | 3,963,424 | Shares | Sole | 2024-02-26 | |
| 2023-09-30 | $13,580,221 | 1,485,801 | Shares | Sole | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||